Brief: AnGes submits CTN of hypertension DNA vaccine
20/07/2017 02:27
July 20 (Reuters) - AnGes Inc 4563.T
* Says it submitted Clinical Trial Notification (CTN) of
hypertension DNA vaccine to Therapeutic Goods Administration
(TGA) in Australia
Source text in Japanese: https://goo.gl/WRF48e
Further company coverage: 4563.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: Tingting.liu@thomsonreuters.com@reuters.net))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001